Pfizer (PFE) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

PFE trades above its 50-day SMA on recent gains from the Metsera acquisition and a drug pricing agreement with the U.S.

Pfizer has beaten its earnings per share (EPS) estimates in its past 12 quarters. Beating EPS estimates hasn't always meant positive movements for Pfizer's share price. The stock's low valuation and ...

Pfizer offers strong dividends, solid cash flow coverage, discounted value and key risks from patent cliffs, pricing and ...

Pfizer PFE recently announced a landmark deal with the Trump administration. Per the deal, Pfizer committed to key measures aimed at lowering prescription drug costs while boosting investment in ...

Pfizer stock (NYSE: PFE) is currently in a significant slump, marking its ninth consecutive day of decline and losing a total of −11% of its value over that period. This sustained sell-off has wiped ...

Pfizer Inc. (NYSE: PFE) is one of the best undervalued stocks to buy under $50. Pfizer Inc. (NYSE:PFE) received a rating ...

Pfizer has long been a solid dividend payer, having raised its dividend annually for 16 years. Its yield is high because the stock price has fallen in recent years. That has given it an appealing ...

Discover why Pfizer Inc. is rated a Strong Buy with 33% upside, robust dividends, and growth prospects ahead. Click for my updated look at PFE stock.